J
James D. Brierley
Researcher at University of Toronto
Publications - 154
Citations - 25190
James D. Brierley is an academic researcher from University of Toronto. The author has contributed to research in topics: Thyroid cancer & Radiation therapy. The author has an hindex of 45, co-authored 147 publications receiving 22608 citations. Previous affiliations of James D. Brierley include Princess Margaret Cancer Centre & University Health Network.
Papers
More filters
Book
AJCC Cancer Staging Manual
Mahul B. Amin,Stephen B. Edge,Frederick L. Greene,David R. Byrd,Robert K. Brookland,Mary Kay Washington,Jeffrey E. Gershenwald,Carolyn C. Compton,Kenneth R. Hess,Daniel C. Sullivan,J. Milburn Jessup,James D. Brierley,Lauri E. Gaspar,Richard L. Schilsky,Charles M. Balch,David P. Winchester,Elliot A. Asare,Martin Madera,Donna M. Gress,Laura R. Meyer +19 more
TL;DR: Purposes and Principles of Cancer Staging and End-Results Reporting are explained.
Journal ArticleDOI
American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
Robert C. Smallridge,Kenneth B. Ain,Kenneth B. Ain,Sylvia L. Asa,Sylvia L. Asa,Keith C. Bible,James D. Brierley,James D. Brierley,Kenneth D. Burman,Electron Kebebew,Nancy Y. Lee,Yuri E. Nikiforov,M. Sara Rosenthal,Manisha H. Shah,Ashok R. Shaha,R. Michael Tuttle +15 more
TL;DR: These are the first comprehensive guidelines for ATC and provide recommendations for management of this extremely aggressive malignancy.
Journal ArticleDOI
Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma
Alexis Bujold,Christine Massey,John Kim,James D. Brierley,Charles Cho,Rebecca Wong,Rob Dinniwell,Zahra Kassam,Jolie Ringash,Bernard Cummings,Jenna Sykes,Morris Sherman,Jennifer J. Knox,Laura A. Dawson +13 more
TL;DR: Results of prospective trials of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma with strong rationale for studying SBRT for HCC in a randomized trial are described.
Journal ArticleDOI
Outcomes of patients with differentiated thyroid carcinoma following initial therapy.
Jacqueline Jonklaas,Nicholas J. Sarlis,Nicholas J. Sarlis,Danielle R. Litofsky,Kenneth B. Ain,S. Thomas Bigos,James D. Brierley,David S. Cooper,Bryan R. Haugen,Paul W. Ladenson,James Magner,Jacob Robbins,Douglas S. Ross,Monica C. Skarulis,Harry R. Maxon,Steven I. Sherman +15 more
TL;DR: It is confirmed that near-total thyroidectomy is indicated in high-risk patients and radioactive iodine therapy is beneficial for stage II, III, and IV patients, and it is shown for the first time that superior outcomes are associated with aggressive thyroid hormone suppression therapy in high risk patients, but are achieved with modest suppression in stage II patients.
Journal ArticleDOI
Global trends in colorectal cancer mortality: projections to the year 2035
Marzieh Araghi,Isabelle Soerjomataram,Mark A. Jenkins,James D. Brierley,Eva Morris,Freddie Bray,Melina Arnold +6 more
TL;DR: Mortality rates for colon cancer are predicted to continue decreasing in the majority of included countries from Asia, Europe, North America and Oceania, except Latin America and Caribbean countries, and the number of deaths is expected to rise in all countries for both colon and rectal cancer by 60.0% and 71.5% until 2035 due to population growth and ageing.